A practical reference on epitalon: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-05 and is reviewed periodically as new material appears.
Epitalon emerged from research conducted in Saint Petersburg by Vladimir Khavinson and colleagues, who studied short peptides as potential regulators of aging. The work built on epithalamin, a pineal gland extract reported to influence neuroendocrine function. Epitalon was designed as a synthetic counterpart with a defined sequence, allowing reproducible experiments that extracts could not support. Early publications described effects on melatonin rhythms and lifespan in animal models. These findings circulated mainly in Russian-language journals during the 1990s, which limited their visibility among English-speaking researchers.
The most widely cited claim is that epitalon activates telomerase and thereby extends telomere length. Supporting evidence comes largely from cultured human cells, where treatment was associated with increased telomerase activity and delayed replicative senescence. Telomerase activation is a biologically consequential effect, since the enzyme is largely silenced in most somatic cells. However, the route by which a short peptide would reach and act on the enzyme's regulatory machinery has not been established. Independent replication in human trials is scarce, so the link between cell-culture observations and whole-body aging remains an open question.
Human data are limited to small studies, often without the randomization, blinding, or control groups expected in contemporary clinical research. Reported outcomes have included changes in melatonin levels, immune markers, and subjective measures, but sample sizes were generally too small to support firm conclusions. Some reviews treat the peptide as promising while noting methodological weaknesses; others question whether the observed effects are specific. The compound is frequently discussed in longevity-focused communities, where enthusiasm often outpaces the published evidence. Separating established findings from speculation is therefore important when reading summaries of this research.
The peptide is a synthetic analogue of epithalamin, a preparation extracted from bovine pineal glands. Investigators sought a short, chemically defined molecule that would reproduce some of the endocrine and gerontological observations attributed to the glandular extract. Proposed mechanisms centre on induction of telomerase activity, an effect reported in cultured human somatic cells in the early 2000s, together with influences on melatonin secretion and neuroendocrine regulation. Those mechanisms remain incompletely characterised, and the reported telomerase response has not been consistently reproduced by independent groups working in comparable systems.
Published work on this compound consists mainly of in vitro experiments, animal studies, and small clinical investigations, a substantial share of which appeared in Russian-language journals. Sample sizes are generally small, control conditions differ between studies, and several endpoints rely on markers whose clinical meaning is itself debated. Reviews of the longevity field treat the peptide as an early example of telomerase-directed research rather than an established intervention. Regulatory treatment varies by country: some jurisdictions place it under prescription controls, others treat it as a laboratory material, and importation may be restricted regardless of local status.
| Property | Value | Notes |
|---|---|---|
| Peptide sequence | Ala-Glu-Asp-Gly | Single-letter form AEDG |
| Compound class | Synthetic tetrapeptide | Not a natural free peptide |
| Research origin | Russian gerontology institutes | Developed during the 1990s |
| Main research claim | Telomerase activation | Evidence mainly from cultured cells |
| Regulatory status | Not an approved drug | Handled as a research material |
Verification of a sample usually begins with reversed-phase high-performance liquid chromatography, which resolves the peptide from truncated sequences and other impurities and expresses purity as a percentage of total peak area. Mass spectrometry by electrospray ionisation or matrix-assisted laser desorption supplies an independent check, because the measured mass can be compared against the theoretical value for AEDG. Amino acid analysis or tandem mass spectrometry sequencing can confirm residue order. Each of these methods answers a different question: a purity figure does not establish identity, and an identity match does not establish how much of the material is intact peptide.
The molecule is a short, linear, hydrophilic peptide that dissolves readily in water or aqueous buffer. Its principal chemical liabilities are hydrolytic rather than oxidative, since it contains no cysteine, methionine, or tryptophan residues. The aspartate–glycine step is a recognised site for aspartimide formation under mildly acidic or basic conditions, generating isoaspartate and succinimide-related products over time. Desiccated lyophilised powder held at −20 °C is comparatively stable, whereas dilute solutions degrade faster and are best frozen as single-use aliquots rather than thawed repeatedly.
No pharmacopoeial monograph exists for this peptide, so quality rests on the supplier's internal specifications and on whatever independent testing a purchaser arranges. Certificates of analysis differ widely in which tests they report and in the limits applied. The counter-ion introduced during purification, commonly acetate or trifluoroacetate, changes the net peptide content of a given mass of powder, so two samples of equal weight may not contain equal amounts of the active sequence. Third-party laboratories can verify purity, identity, residual solvents, and counter-ion content for a fee, which makes documentation more informative than labelling.
Epitalon is a synthetic tetrapeptide with the residue sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. Its monoisotopic mass is approximately 390.35 daltons, and it is usually supplied as a lyophilised trifluoroacetate or acetate salt. The compound was derived from a pineal gland extract called epithalamin, a heterogeneous preparation investigated in the former Soviet Union. Researchers associated with the Saint Petersburg Institute of Bioregulation and Gerontology described the tetrapeptide as a constituent fragment of that extract. Commercial material is offered as a laboratory reagent rather than as a finished pharmaceutical product.
Literature searches for this compound must account for several spelling variants. Indexing databases contain epitalon, epithalon, epithalone, and AEDG, and relevant records are scattered across Russian-language and English-language journals that do not consistently cross-cite. Early publications describe the parent extract as a mixture of many peptides, whereas later work addresses the single synthetic tetrapeptide. That shift in nomenclature complicates comparison between studies, because extract data and tetrapeptide data are sometimes cited interchangeably. A search strategy omitting the alternate spellings will return an incomplete set of references.
Reported biological findings come mainly from cell culture and rodent experiments. Those studies describe changes in telomerase catalytic subunit expression, melatonin rhythm amplitude, and antioxidant enzyme activity after peptide exposure. Human data are sparse and consist of small trials with limited blinding and inconsistent endpoints. The proposed mechanisms remain hypotheses rather than established facts, and there is no consensus on whether effects observed in animals carry over to people. Independent replication outside the original research groups is limited, which is a recognised gap in the published literature.
Storage practice centres on limiting moisture, oxygen, and repeated temperature cycling. Freeze-dried powder is generally held desiccated at minus twenty degrees Celsius or colder and protected from light. Reconstituted solutions are markedly less stable, and the aspartate-glycine junction is prone to succinimide formation at neutral to mildly alkaline pH. Portioning material into single-use aliquots reduces degradation compared with repeated freeze-thaw cycles. Stability data specific to this tetrapeptide remain scarce, so most handling guidance is extrapolated from general peptide chemistry rather than measured directly.
Documentation accompanying research peptides usually includes a certificate of analysis listing the batch number, purity figure, and test methods applied. Buyers comparing suppliers should check whether the reported purity refers to chromatographic area or to a mass-balance calculation, because the two are not equivalent. Counter-ion content, residual solvents, and water content are sometimes omitted from such certificates even though they affect the actual peptide mass present. Independent verification through a second laboratory is the most direct way to confirm that a supplied material matches its label.
Purity assessment of peptide reagents normally relies on reversed-phase high-performance liquid chromatography. A gradient of acetonitrile in water with trifluoroacetic acid, paired with a C18 stationary phase, separates the target tetrapeptide from truncated sequences and deletion analogues. Detection at 214 nanometres exploits absorbance of the peptide backbone, since the molecule contains no aromatic residue. Results are expressed as a percentage of total peak area. Values above ninety-five percent are typical for research-grade material, although reporting conventions vary between suppliers.
=== Hair === Hair is capable of recording medium to long-term or high dosage substance abuse. Chemicals in the bloodstream may be transferred to the growing hair and stored in the follicle, providing a rough timeline of drug intake events. Head hair grows at rate of approximately 1 to 1.5 cm a month, and so cross sections from different sections of the follicle can give estimates as to when a substance was ingested. Testing for drugs in hair is not standard throughout the population. The darker and coarser the hair the more drug that will be found in the hair. If two people consumed the same amount of drugs, the person with the darker and coarser hair will have more drug in their hair than the lighter haired person when tested. This raises issues of possible racial bias in substance tests with hair samples. Hair samples are analyzed using enzyme-linked immunosorbent assay (ELISA). In ELISA, an antigen must be immobilized to a solid surface and then complexed with an antibody that is linked to an enzyme.
=== Cavity-enhanced absorption spectrometry (CEAS) === The second way of improving the detectability of TDLAS technique is to extend the interaction length. This can be obtained by placing the species inside a cavity in which the light bounces back and forth many times, whereby the interaction length can be increased considerably. This has led to a group of techniques denoted as cavity enhanced AS (CEAS). The cavity can either be placed inside the laser, giving rise to intracavity AS, or outside, when it is referred to as an external cavity. Although the former technique can provide a high sensitivity, its practical applicability is limited because of all the non-linear processes involved. External cavities can either be of multi-pass type, i.e. Herriott or White cells, of non- resonant type (off-axis alignment), or of resonant type, most often working as a Fabry–Pérot (FP) etalon. Multi-pass cells, which typically can provide an enhanced interaction length of up to ~2 orders of magnitude, are nowaday common together with TDLAS. Resonant cavities can provide a much larger path length enhancement, in the order of the finesse of the cavity, F, which for a balanced cavity with high reflecting mirrors with reflectivities of ~99.99–99.999% can be ~ 104 to 105. It should be clear that if all this increase in interaction length can be utilized efficiently, this vouches for a significant increase in detectability.
== Accuracy == CGMs do not always produce readings identical to fingerstick blood glucose tests due to a lag between interstitial and blood glucose levels, especially during rapid changes. Differences of up to 20% are considered normal. The Dexcom G6 and G7 CGMs allows for user calibration based on their fingerstick blood glucose readings if needed. CGM readings are most accurate when glucose levels are stable.
==== Blebs ==== Blebs are spherical membrane protrusions that are involved in both apoptosis and cell movement. The driving force behind bleb extension is hydrostatic pressure, rather than actin filament elongation which drives lamellipodia, filopodia and invadopodia extension. Blebs are formed by actomyosin contraction, which causes the delamination of the plasma membrane from the actin cortex or a focal rupture of the actin cortex. They are then stabilized via actin cortex reassembly and finally retracted via actomyosin contraction. In migrating cells a front-rear polarity is established, with bleb formation restricted to the leading edge, allowing for directed movement.
Sources: en.wikipedia.org
Glycoproteins are proteins which contain oligosaccharide (sugar) chains covalently attached to amino acid side-chains. The carbohydrate is attached to the protein in a cotranslational or posttranslational modification. This process is known as glycosylation. Secreted extracellular proteins are often glycosylated. In proteins that have segments extending extracellularly, the extracellular segments are also often glycosylated. Glycoproteins are also often important integral membrane proteins, where they play a role in cell–cell interactions. It is important to distinguish endoplasmic reticulum-based glycosylation of the secretory system from reversible cytosolic-nuclear glycosylation. Glycoproteins of the cytosol and nucleus can be modified through the reversible addition of a single GlcNAc residue that is considered reciprocal to phosphorylation and the functions of these are likely to be an additional regulatory mechanism that controls phosphorylation-based signalling. In contrast, classical secretory glycosylation can be structurally essential. For example, inhibition of asparagine-linked, i.e. N-linked, glycosylation can prevent proper glycoprotein folding and full inhibition can be toxic to an individual cell.
Collins correctly identified a photo of Elton John, however Hasselhoff mistook a photo of Debbie Harry for Cyndi Lauper and they were eliminated in the first round with a score of 147. In April 2025, Collins attended the "24 Hour Piano-thon" at Liverpool Street Station which was in promotion of the third series of the Channel 4 music competition show The Piano. Collins played a rendition of Chopsticks on the piano, before performing I Wanna Dance with Somebody (Who Loves Me) by Whitney Houston alongside the Keynotes Choir. In March 2026, after attending the Cheltenham Festival the previous year and not winning anything, Collins returned to the event and ultimately won £20,000 throughout the day, which included £5,000 on one bet after she bet on a horse who won its race with odds of 9/1. In an interview during the ITV Racing coverage, Collins said attending the event had "ignited a fire in her" and encouraged other people, especially women to attend, describing it as "not just a man's sport" and added that she'd probably earn enough money at next year's event to "buy the Cheltenham Racecourse". In April 2026, Collins returned to I'm a Celebrity, 11 years after her original appearance, to take part in the second series of the "All Stars" spin-off I'm a Celebrity... South Africa, which was filmed in September 2025 and featured campmates from previous series.
4-Hydroxyatomoxetine, the major active metabolite of atomoxetine in CYP2D6 extensive metabolizers, has been found to have sub-micromolar affinity for opioid receptors, acting as an antagonist at the μ-opioid receptor (MOR) and as a partial agonist at the κ-opioid receptor (KOR). The affinities (IC50Tooltip half-maximal inhibitory concentration) of 4-hydroxyatomoxetine were 164 nM for the MOR, 88 nM for the KOR, 1,490 nM for the δ-opioid receptor (DOR), and >5,000 nM for the nociceptin receptor (ORL-1). Atomoxetine itself showed dramatically lower affinities (e.g., 25- to 50-fold). It is not known whether the actions of 4-hydroxyatomoxetine at the opioid receptors leads to CNS-related adverse effects with atomoxetine. Atomoxetine does not alter locomotor activity in rodents, in contrast to stimulants like amphetamine. In addition, atomoxetine does not produce self-administration in monkeys, also in contrast to stimulants like amphetamine. The drug does not produce stimulant-like effects, euphoria, or reinforcing effects in humans, instead increasing negative and unpleasant ratings at the highest assessed doses. Atomoxetine has been found to increase cortisol levels in humans.
Sources: en.wikipedia.org
Vladimir Khavinson and colleagues at research institutes in Saint Petersburg developed and studied the peptide. Their program examined short peptides as regulators of aging and neuroendocrine function. Epitalon was one of several compounds produced by that group.
That question is not settled. Cell culture studies have reported increased telomerase activity after treatment, but comparable evidence from controlled human trials is lacking. Any claim about telomere lengthening in people should be treated as unproven.
It has not completed the large, controlled trials required for drug approval in major jurisdictions. Most human reports involve small samples and limited follow-up. As a result, it is sold as a research chemical rather than a licensed pharmaceutical product.
Epitalon is a synthetic four-amino-acid peptide with the sequence alanine–glutamate–aspartate–glycine, also written AEDG. It was developed in Russian gerontology research and is studied for proposed effects on telomerase, melatonin regulation, and neuroendocrine function. It is not an approved pharmaceutical in the United States or the European Union.